Last reviewed · How we verify
Ancef In Sodium Chloride 0.9% In Plastic Container (CEFAZOLIN)
Ancef In Sodium Chloride 0.9% In Plastic Container (Cefazolin) is a cephalosporin antibacterial medication originally developed by GlaxoSmithKline and currently owned by the same company. It is a small molecule modality that has been FDA-approved since 1973 for various bacterial infections, including endocarditis, pneumonia, and urinary tract infections. As an off-patent medication, it is available from multiple generic manufacturers. Key safety considerations include its potential to cause allergic reactions and interactions with other medications. Cefazolin is administered intravenously and has a half-life of 1.7 hours.
At a glance
| Generic name | CEFAZOLIN |
|---|---|
| Sponsor | GSK |
| Drug class | Cephalosporin Antibacterial |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1973 |
Approved indications
- Bacterial endocarditis
- Bacterial pneumonia
- Bacterial septicemia
- Bacterial urinary infection
- Cholangitis
- Genitourinary Tract Infections
- Infection of biliary tract
- Infection of bone
- Infection of skin AND/OR subcutaneous tissue
- Infectious disorder of joint
- Lower respiratory tract infection
- Pneumonia due to Streptococcus
- Prevention of Perioperative Infection
- Staphylococcal pneumonia
Common side effects
- Pseudomembranous colitis
- Anorexia
- Nausea
- Vomiting
- Diarrhea
- Stevens-Johnson syndrome
- Anaphylaxis
- Neutropenia
- Leukopenia
- Thrombocytopenia
- Thrombocythemia
- Hepatitis
Key clinical trials
- Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study (PHASE4)
- IO Vancomycin Spine (PHASE2,PHASE3)
- Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre (NA)
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- Antibiotics for Prevention of Infection Following Orthognathic Surgery (PHASE4)
- Prophylaxis Against Surgical Site Infections Using Local as Well as Systemic Antibiotic (NA)
- Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial (PHASE4)
- Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: